- Leading world ESG scores company Sustainalytics notes Grünenthal is within the high 5 % amongst its friends within the pharmaceutical subindustry
- Grünenthal is categorized as “medium risk”, inserting it forward of its key subindustry friends and in the identical league as multinational corporations like Pfizer and Roche
Aachen, Germany, 7 April 2021 – Grünenthal, a world science-based pharmaceutical firm, in the present day introduced that Sustainalytics, a Morningstar firm and a globally-recognized supplier of ESG analysis, scores and information, has assessed it as having total medium ESG threat. In addition, Sustainalytics acknowledged that Grünenthal has a robust administration of its ESG dangers. This locations Grünenthal within the high 5 % of the worldwide prescribed drugs subsector.
“The long-term success of companies can no longer be measured by financial success alone. As a science-based company, Grünenthal strives to make a net-positive impact on the society,” stated Gabriel Baertschi, CEO Grünenthal. “While we are proud to see our efforts recognized in this ESG rating, we know that a big part of the journey is still ahead of us. Building on our foundation as a responsible business, we will now integrate sustainability even more closely in our core strategy.”
Grünenthal was evaluated by Sustainalytics based mostly on its ESG Risk Ratings framework, which focuses on publicity and administration of an organization’s materials ESG points. “Exposure” displays the diploma to which an organization’s enterprise worth is uncovered to materials ESG points together with moral advertising and marketing, medical trial transparency, whistleblowing, corruption and bribery. “Management” measures an organization’s preparedness and monitor file in managing its publicity to materials ESG points by means of its insurance policies, programmes, trainings and administration programs.
The firm’s ESG Risk Rating is out there on Sustainalytics’ web site. All information talked about is as of 6 April 2021 and confer with the Grünenthal Pharma GmbH & Co. KG.
About Grünenthal’s ESG efforts
Grünenthal has been focusing its Environmental, Social & Governance (ESG) efforts on 4 pillars: educate about ache therapy and accountable use of opioids; guarantee entry to medicines, innovate ache administration, and lift consciousness for “pain as a disease”:
Educate about ache therapy and accountable use of opioids
Grünenthal has to date reached round 65,000 well being care professionals in its efforts to coach the healthcare sector about ache administration and enhance the affected person outcomes from ache therapy. As a pacesetter in ache innovation and as an opioid producer, Grünenthal is very dedicated to making sure that its staff, clients, sufferers and in addition its companions have an intensive understanding of the corporate’s stance on the accountable medical use of opioids in ache. The firm has fostered a mindset shift alongside the complete worth chain by guaranteeing that each one opioid-related supplies comprise Grünenthal’s assertion on accountable use of opioids – clearly highlighting the dangers and advantages of this class of medicines. In addition, Grünenthal had established a devoted standing governance physique to offer and promote clear steerage, coherent habits, steady enchancment, coaching and management mechanisms.
Ensure entry to medication
Grünenthal is dedicated to making sure the provision of key medicines to handle unmet medical wants within the markets we serve. In the US, for example, 5 million sufferers are in want of neuropathic ache therapy related to diabetes. With the US FDA label extension of certainly one of our non-opioid ache medicines for the therapy of neuropathic ache related to diabetic peripheral neuropathy of the ft, Grünenthal has ensured sufferers get entry to this a lot wanted therapy. At the identical time, the corporate is targeted on addressing unmet therapeutic wants in underserved markets by providing specialised non-opioid ache medicines.
Innovate ache administration
Grünenthal’s analysis and growth technique focuses on tackling in ache and collaborating with companions to handle the massive unmet wants in ache. Through biennial grants of €200,000 offered by Grünenthal and the EFIC, the corporate helps younger scientists early of their profession in finishing up modern medical ache analysis. Since basis of the EFIC-Grünenthal Grant in 2004, roughly €1.6 million was awarded to fund 65 tasks. In addition, to drive patient-centric innovation in power ache and neurological problems and award patient-centric and scientifically strong innovation, the corporate helps the Brain, Mind, and Pain Patient-Centered Innovation Grant, which awards €90,000 biennially to analysis proposals to encourage patient-centered innovation that results in enhancements within the life situations of ache sufferers.
Raise consciousness for “pain as a disease”
Chronic ache is a gigantic world well being downside affecting round 10% of the world’s inhabitants. Grünenthal raises consciousness concerning the impression of ache by supporting a multi-stakeholder platform, referred to as the Societal Impact of Pain platform, which fosters the event of ache insurance policies on nationwide degree. With Grünenthal’s Pain Toolkit, the corporate has established a sensible software that gives sufferers with helpful suggestions and expertise within the type of explanations, infographics and movies, on how one can self-manage ache. Moreover, Grünenthal has a long-standing ardour for preserving the dignity and high quality of life on the finish stage of individuals’s lives. The Grünenthal Foundation for Palliative Care promotes science and analysis in palliative care and the take care of severely or terminally unwell individuals in Europe in addition to in Latin America.
Besides these 4 focus pillars, Grünenthal is protecting the complete vary of the Environmental, Social and Governance spectrum with numerous initiatives and measures:
Our efforts to advertise sustainable growth embody defining concrete targets for the operations of our 5 manufacturing websites, throughout our provide chain and all of our associates throughout the globe by following main worldwide requirements for setting, well being and security. We acquire and analyze information from our manufacturing websites and use it to constantly enhance effectivity, whereas additionally decreasing power consumption and minimizing waste based mostly on strategic method of zero waste to landfill programme.
Caring for its staff and for the communities the place we function is essential to Grünenthal’s enterprise conduct. Grünenthal provide its staff an thrilling working setting and wide-ranging particular person growth alternatives. It is the corporate’s purpose to take care of excessive ranges of engagement and to strengthen the corporate as a Great Place to Work®. Grünenthal promotes a vibrant, high-performance tradition and brings it to dwell by means of a shared set of values. These are supported by particular behaviours that information the decision-making. Grünenthal ensures excellent outcomes are recognised and rewarded. For instance, the corporate celebrates distinctive contributions every year with its Grünenthal Global Excellence Award.
Sound governance is essential to safeguard the corporate’s license to function and proceed offering medicines to sufferers in want. Grünenthal has a complete compliance and ethics administration system which gives a transparent framework for our selections and actions. Grünenthal’s Code of Conduct for workers reiterates the corporate’s robust dedication to the best moral requirements whereas the Code of Conduct for Business Partners ensures enterprise relationships based mostly on a reciprocal dedication to accountable habits. Grünenthal has an exterior Ethics Helpline for 24/7 nameless reporting in place to make sure compliance with the Code of Conduct. Grünenthal can be dedicated to full disclosure of transfers of worth to healthcare professionals, healthcare organizations and affected person organizations.
Grünenthal is a world chief in ache administration and associated ailments. As a science-based, privately-owned pharmaceutical firm, we’ve a protracted monitor file of bringing modern remedies and state-of-the-art applied sciences to sufferers worldwide. Our objective is to alter lives for the higher – and innovation is our ardour. We are focussing all of our actions and efforts on working in the direction of our imaginative and prescient of a world freed from ache.
Grünenthal is headquartered in Aachen, Germany, and has associates in 29 nations throughout Europe, Latin America and the US. Our merchandise can be found in additional than 100 nations. In 2020, Grünenthal employed round 4,500 individuals and achieved gross sales of € 1.three bn.
More data: www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group
For additional data, please contact:
Florian Dieckmann, Head Global Communications, +49 241 569 2555, Florian.email@example.com
Fabia Kehren, Head External Communications & Editorial Management,
+49 241 569-3269
Grünenthal GmbH, 52099 Aachen, Germany